NewAmsterdam Pharma is developing obicetrapib, a drug with potential to reduce cardiovascular risk beyond just lowering LDL cholesterol. The company's valuation reflects optimism about its drug pipeline rather than current sales. Critical upcoming events include European regulatory decisions in the second half of 2026, interim results from the PREVAIL trial expected between late 2026 and early 2027, and top-line data from the RUBENS study by the end of 2026. The company has a strong financial position to support these milestones and a potential U.S. launch, reducing near-term funding concerns despite still being pre-commercial.
PayPal's board has reportedly rejected an offer valuing the company at $60.50 per share, considering it inadequate. This comes as PayPal's stock currently trades at around $56 per share. The board's stance suggests they believe the company's value is...
Noah Holdings Limited is rated as a BUY, trading at a low forward price-to-earnings ratio of 6x, supported by robust expected earnings per share growth and an attractive 8% dividend yield. The company’s future earnings are expected to benefit from AI...
JPMorgan Chase demonstrates strong earnings power with normalized EPS near $25 and a robust balance sheet supporting ongoing shareholder returns. Its diversified business segments, especially commercial/investment banking and asset/wealth management,...
As of July 25, 2026, ten public companies collectively hold over 1 million bitcoin, with Strategy (formerly MicroStrategy) leading by a wide margin at 843,775 BTC. While Strategy's bitcoin holdings continue to grow, its stock has fallen 40% in 2026 d...
Visa continues to dominate as a global payment processor with strong revenue and transaction growth in fiscal 2026. Despite its solid fundamentals and innovations in stablecoin platforms, the current stock valuation is considered too high to upgrade ...
